Trial of ARX517 Doses First Patient With a PSMA-Expressing Solid Tumor

To address over expression of the prostate specific membrane antigen in men with prostate cancer and other solid tumors, a phase 1 study of the novel anti-PSMA antibody drug conjugate, ARX517, has been administered to the first patient.

To address over expression of the prostate specific membrane antigen (PSMA) in men with prostate cancer and other solid tumors, a phase 1 study of the novel anti-PSMA antibody drug conjugate (ADC), ARX517, has been administered to the first patient, according to a press release from Ambrx.

ARX517 first demonstrated promise in preclinical models for prostate cancer when the pharmacokinetics (PK) and the toxicity profile were adequate in both enzalutamide (Xtandi)-sensitive and -resistant tumors. Now, the multicenter, open-label, dose-escalation phase 1 study (APEX-01; NCT04662580) will assess the safety, pharmacokinetics (PK), and anti-tumor activity of the agent in patients with PSMA-expression prostate, pancreatic, lung, and ovarian cancers.

“I am excited to announce that we dosed our first patient in our phase 1 trial, and thus have taken the first steps in evaluating the potential clinical benefit of ARX517 in cancer patients with tumors overexpressing PSMA,” said Feng Tian, PhD, chairman of the board, president, and chief executive officer of Ambrx. “ARX517 is the second ADC in our internal pipeline to enter the clinic...”

APEX-01 will enroll approximately 76 patients who will be divided into 6 dose cohorts and evaluated in 2 parts. The doses of ARX517 in the study will range from 0.32 mg/kg to 2.0 mg/kg. At all dose levels evaluated, patients will receive treatment every 3 weeks by intravenous infusion. The number of patients included in part 2 of the study will not exceed 40, according to Ambrx.

Safety/tolerability is the key primary end point of the study in part 1 along with determining the maximum-tolerated dose of ARX517 and establishing the recommended phase 2 dose (RP2D). In part 2, the primary end point of the study is to further assess the safety and tolerability of ARX517 at the RP2D. PK and the presence of anti-drug antibodies from baseline, during treatment, and at follow-up are the secondary end points of the study. Investigators will also explore surrogate biomarkers during the study, including circulating tumor cells, PSA, and imaging.

The study is actively enrolling male patients aged 18 years or older with pathologically confirmed adenocarcinoma of the prostate and other solid tumors. All patients are required to have metastatic disease by computed typography, an ECOG performance status of 0 or 1 at screening, adequate organ function, a life expectancy of at least 6 months at screening and have discontinued any radiotherapy 4 weeks prior to the start of the study in order to be eligible for enrollment.

Patients with prostate cancer must meet all the overall inclusion requirements but also be on ongoing hormone therapy, be previously treated with an FDA-approved drug for the treatment of metastatic castration-resistant prostate cancer, have disease progression, and have discontinued any non-steroidal anti-androgens 4 weeks prior to joining APEX-01.

The first recruitment site for the first-in-human study of ARX517 in PSMA-expressing solid tumors is the Urology Cancer Center of the XCancer Research Network located in Omaha, Nebraska. The site study lead is Luke Nordquist, MD, FACP.

Reference:

Ambrx announces first patient dosed in a phase 1 trial for ARX517, an ADC in development to treat PSMA expressing tumors. News release. August 3, 2021. Accessed August 3, 2021. https://bit.ly/3ChmDaH